Glaxo Specialty (Medical Benefit) 49401010101 - … | USA MedPremium
Benlysta® Belimumab 120 mg Injection for SLE and Lupus Nephritis
USAMP#78015276SKU: 49401010101Benlysta®
License Required
Product Spotlight
Benlysta® is a targeted B-lymphocyte stimulator (BLyS)-specific inhibitor, designed for the management of systemic lupus erythematosus (SLE) in patients aged 5 years and above with active, autoantibody-positive disease, alongside standard therapy.
It is also approved for adult patients suffering from active lupus nephritis as part of their comprehensive treatment plan.
Benlysta® (belimumab) is presented as a 120 mg/5 mL single-use vial, ensuring a sterile, preservative-free administration for immune system modulation.
As an immunosuppressive agent, it plays a crucial role in controlling the progression of lupus by specifically inhibiting the BLyS protein, which is implicated in the disease's pathogenesis.
